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Background: In chemotherapy trials quality of life (QOL) is assessed mostly at the days of chemotherapy administration
(i.e. event-driven) during treatment and follows fixed time intervals in the aftercare phase (i.e. time-driven). Specific QOL
impairments and treatment side-effects are known to be time dependent following different trajectories. Therefore, acute
problems are likely to be missed if assessments are done infrequently or at inappropriate time points. Since the planning
of supportive care interventions during chemotherapy depends on knowledge about symptom trajectories, such
information may be of substantial importance to a clinician.
Methods: Cancer patients receiving chemotherapy at Kufstein County Hospital were assessed using an electronic
version of the EORTC QLQ-C30 at the day of chemotherapy administration at the hospital. One and two weeks
later assessments were repeated via the internet while patients were at home. Assessments at home and the
hospital were conducted using the web-based software CHES. Data were analysed by means of linear mixed models.
Results: A sample of 54 chemotherapy outpatients participated in electronic QOL assessments at the hospital and at
home. For 9 out of the 15 QOL domains of the EORTC QLQ-C30 patients reported increased burden one week after
chemotherapy administration compared to the day of chemotherapy administration. Most pronounced differences
were found for Fatigue, Constipation, and Appetite Loss.
Conclusions: Our results indicate that patients experience most severe QOL impairments in the week following
chemotherapy administration. This is a period that is usually not covered by QOL assessments in chemotherapy trials
which may result in underestimation of true treatment burden. Our findings suggest to conduct QOL assessments not
only event- or time-driven, but to rely on specific hypotheses on symptom and functioning trajectories.Background
The value of the information gained from patient-
reported outcome (PRO) assessments in clinical trials
and daily clinical practice relies substantially on the use
of valid and reliable measurement instruments, being
appropriate for the targeted patient group, and on the
correct timing of the PRO assessment [1]. Whereas
investigation of psychometric properties of PRO instru-
ments and their applicability to specific patient groups
has been a major research focus, the timing of the as-
sessment has gained less attention. In clinical trials and* Correspondence: johannes.giesinger@i-med.ac.at
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unless otherwise stated.in daily clinical practice PRO assessment is either event-
driven (e.g. at every hospital visit) or time-driven (e.g.
every three months) [2]. Such straightforward schedules
allow simplifying data collection logistics, but may also
have an impact on the collected PRO scores as symptom
burden, functioning, and quality of life (QOL) may not
be assessed at time points giving the most appropriate
picture of their longitudinal development.
To date, only few studies have looked on the impact of
timing of QOL assessments on QOL results. Retrospective
analyses [3-5] of trial data compared assessments at the
day of chemotherapy (CT) administration with deviating
assessments that were collected outside the predefined
time windows. These analyses, considering early or late
assessments as a possible source of measurement error,al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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worse when collected one week after CT administration
compared with later assessments.
According to the clinical model for QOL assessments
suggested by Klee et al. [6] timing of QOL assessments
should not just rely on fixed time patterns or clinical
events, but follow considerations on the hypothesized
course of a symptom or functioning domain. These
authors differentiate between cancer-related symptoms
and symptoms due to other causes, as well as between
acute and chronic treatment side effects.
Defining adequate assessment time points for PROs
appears to be most important for acute side effects, such
as fatigue, nausea/vomiting, diarrhoea and appetite loss,
since due to their limited duration they may be missed if
assessment intervals are too large. Therefore the com-
mon assessment pattern in CT trials administering ques-
tionnaires only at the day of CT administration is likely
to miss time points of high levels of acute side-effects.
This is probably especially true, if CT protocols rely on
three-weekly administration of cytostatic drugs. This
has been shown in a study by Hilarius et al. [7] investi-
gating acute and delayed chemotherapy-induced nausea
and vomiting. The authors found prevalence rates for
both symptoms to be nearly twice as high a week after
CT administration when compared to the day prior to
CT administration.
Inadequate QOL assessment schedules in clinical trials
may result in biased QOL underestimating the true
symptom burden a patient experiences. In comparative
trials differences between chemotherapy regimens with
regard to acute side effects may go unnoticed in case of
infrequent QOL assessments and therefore lead to in-
correct evaluation of the impact of treatments on pa-
tient’s QOL. In daily clinical practice QOL assessments
covering the period following CT administration may
allow timely interventions to manage patients symptom
burden at the moment of highest severity.
Based on such considerations we aim at investigating if
symptom burden and functioning impairments recorded at
the time of CT administration differ substantially from
assessments one and two weeks later, thus requiring more
frequent assessment schedules in future trials or when
monitoring symptoms in daily clinical practice. For this
purpose our study made use of web-technology to extend
PRO assessments beyond the hospital setting. In detail, the
study compares CT patients’ QOL at three time points: at
the day of CT (at the hospital) administration, one week
later and two weeks later (both at home).
Methods
Sample
In this prospective study we recruited cancer patients
undergoing CT at the Department of Internal Medicineat Kufstein County Hospital (Austria) according to the
following inclusion criteria:
 any cancer diagnosis
 CT regimen with 2-weekly or 3-weekly administra-
tion of cytostatic drug
 age above 18
 no obvious cognitive impairments
 no language barriers
 written informed consent
Socio-demographic and clinical patient characteristics
were gathered from the medical charts. Patients were in-
cluded at administration of any CT cycle and then assessed
during multiple cycles. We conducted one assessment
between cycles if patients received a two-weekly regimen
and two if patients received a three-weekly regimen.
The study has been approved by the Ethics Committee
of Innsbruck Medical University.
QOL data capture
Patients’ QOL was assessed with the EORTC QLQ-C30
[8], an internationally validated and widely used ques-
tionnaire to assess QOL, psychosocial burden and phys-
ical symptoms in cancer patients. It consists of five
functioning scales (Physical, Social, Role, Cognitive, and
Emotional Functioning), a scale for Global QOL, and
nine symptom scales (Fatigue, Pain, Nausea/Vomiting,
Dyspnoea, Appetite Loss, Sleep Disturbance, Constipa-
tion, Diarrhoea and Financial Difficulties). The QLQ-
C30 uses a recall period of one week which provided the
rationale for our weekly assessment schedule. This means
that for example an assessment one week after chemo-
therapy administration provides information on the QOL
experienced in the week following chemotherapy, whereas
an assessment at the day of chemotherapy administration
provides information on pre-administration QOL.
After study inclusion patients completed their first
QOL assessment with the QLQ-C30 in the hospital on a
tablet PC supervised by a study nurse who answered
questions concerning the use of the electronic device.
Patients were then offered to complete the follow-up
questionnaires one and two weeks later at home either
via the web-browser on their own computer, or via a
tablet PC that they could obtain from the hospital for
the duration of study participation. In both cases the
patients received an information sheet explaining how to
log on to the system from home and a user name and
password to do so.
Electronic questionnaire administration at the hospital
and at home was done with the Computer-based Health
Evaluation System (CHES) [9,10], a software for PRO
data collection and result presentation in daily clinical
practice and clinical trials.
Table 1 Descriptive statistics for sociodemographic and
clinical variables (n = 54)
Age: Mean (SD) 58.7 (10.8)
Median 61




Mean (SD) 52.5 (70.5)
Median 19
Diagnosis: n (%) Lung cancer 14 (25.9%)
Breast cancer 11 (20.4%)
Lymphoma 8 (14.8%)
Pancreatic or cholangiocellular cancer 8 (14.8%)
Colorectal cancer 7 (13.0%)
Ovarian cancer 4 (7.4%)
Stomach cancer 1 (1.9%)
Oesophagic cancer 1 (1.9%)
Chemotherapy:
n (%)*
Taxane monotherapy 89 (15.9%)
Gemcitabine 59 (10.5%)
Capecitabine plus platin 33 (5.9%)
Irinotecan and capecitabine 33 (5.9%)
Ribomustin 30 (5.3%)
Platin plus etoposid 28 (5.0%)
Taxane plus Bevacizumab 25 (4.5%)




Pemetrexed plus platin 19 (3.4%)








1. Line palliative 183 (32.6%)
2. Line palliative 111 (19.8%)
3. Line or more palliative 92 (16.4%)
*percentages refer to total number of assessments (n = 561).
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Analysis of QOL differences between hospital- and
home-based assessments was done with linear mixed
models. The model comprised assessment time point
within CT cycle (at hospital, 1 week after CT at home,
and 2 weeks after CT at home), time since diagnosis and
the interaction term as fixed effects. In addition, it
employed a 1st order autoregressive covariance structure
and a random intercept at patient level. In this model
the two-way interaction term for time point and time
since diagnosis indicates that the size of the differences
between the three time points (at hospital, 1 week and
2 weeks later) changes over the course of treatment.
The main analysis used the time window of 4–10 days
after hospital-based assessment for the one-week time
point, and 11–17 days for the two-weeks time point. We
would like to note that in our statistical model the QOL
data collected from the same patient during different CT
cycles was summarised time point-wise. This means for
example that for a patient receiving a two-weekly regi-
men, assessments from different cycles were either
classified as “at hospital” or as “one-week follow-up” and
then compared against each other.
To investigate robustness of our results we performed
additional sensitivity analyses using different time win-
dows for the follow-up time points.
According to Osoba et al. [11] a difference of at least 5
points is considered a small clinical difference on the
QLQ-C30 scales, whereas a difference of at least 10
points reflect a moderate clinical difference. This is in
line with the thresholds for clinical relevance suggested
by Ringash et al. [12]. As additional indicators of differ-
ences in symptom burden at home and in the hospital
we calculated percentages of patients for which hospital-
reported symptom burden is at least 10 points (i.e. mod-
erately) worse than symptom burden reported at home.
Results
Patient characteristics
One hundred sixty-six patients were eligible for study
participation, of which 55 patients (33.1%) were willing to
complete questionnaires electronically (including web-
based assessments at home). One of the 55 patients com-
pleting questionnaires web-based at home did not provide
corresponding assessments at the hospital and was there-
fore excluded from analysis. Thirty-four patients obtained
a tablet PC from the hospital for questionnaire completion
at home and 20 patients used their own computer to
access the questionnaires online.
One hundred and eleven patients did not want to
complete questionnaires electronically at home (51 pre-
ferred being assessed at home via phone interviews, 28
were skeptic about QOL assessments and electronic
assessments in general, 15 wanted to be assessed only atthe hospital, 6 were in a poor physical condition, and 11
refused for other reasons). Details on the feasibility of
our web-based assessments are published elsewhere.
Patients participating in phone interviews were ex-
cluded from analysis as mode of administration (inter-
view vs. electronic questionnaire) would otherwise be a
source of bias [13-15]. Participants and non-participants
did not differ significantly with regard to sex (55.6% vs.
52.3% male; p = 0.741), but with regard to age (58.7 vs.
68.7 years; p < 0.001).
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10.8) and 55.6% were men. Most frequent diagnoses
were lung cancer (25.9%) and breast cancer (20.4%).
Total number of assessments was 561, i.e. patients
completed the QLQ-C30 10.4 times on average. 41.1% of
the assessments were conducted electronically at the
hospital at the day of CT administration, 36.1% one week
(4–10 days) later, and 22.7% two weeks (11–17 days)
later at home via internet.
Most patients (68.8%) were receiving CT with pallia-
tive intent, with taxane monotherapy (15.9%) and gemci-
tabine monotherapy (10.5%) being the most frequent
regimens. For further details see Table 1.
Comparison of QOL assessments at the hospital and
at home
The comparison of the QOL assessments at the hospital
and one and two weeks later at home showed a consist-
ent pattern across many functioning and symptom scales
of the QLQ-C30. The highest symptom burden was
usually observed one week after CT administration and
partial or complete recovery after two weeks to those
levels reported at the hospital visit.
Assuming a five-point-difference as threshold for clin-
ical relevance [11] the following scales showed clinically
relevant (and statistically significant) mean differences
between the hospital-based assessment and the follow-
up one week later at home:
Constipation (9.8 points), Fatigue (9.1 points), Appetite
Loss (8.9 points), Sleeping Disturbances (8.4 points), Role
Functioning (−7.1 points), Physical Functioning (−6.6 points),
Nausea/Vomiting (6.6 points), Global QOL (−5.5 points),
and Social Functioning (−5.2 points). All differences
indicated higher impairment at home one week after
CT administration compared to the assessment at the
hospital. Further details are given in Tables 2 and 3 as
well as in Figures 1 and 2.
We did not find a significant interaction of time since
diagnosis and assessment time point for any of the
QLQ-C30 scales, i.e. the observed differences betweenTable 2 EORTC QLQ-C30 functioning domains and time point
assessments)
EORTC QLQ-C30 At the hospital A
(1 wEstimated mean (95% CI)
Physical Functioning 81.4 1w (76.9-86.0) 74.8 Ho
Social Functioning 72.3 1w, 2w(66.5-78.0) 67.1
Role Functioning 64.1 1w(58.2-70.0) 57.0 Ho
Emotional Functioning 71.9 1w(67.2-72.6) 67.9 H
Cognitive Functioning 89.6 1w(85.6-96.5) 86.4 H
Global QOL 66.5 1w, 2w(62.6-70.5) 61.0
superscript numbers indicate significance (p < 0.05) of post-hoc group comparisons
score differences to the hospital-based assessment exceeding 5 points are given inthe hospital-based assessment and the two assessments
at home did not change significantly over the course of
treatment.
With regard to the proportion of assessments showing
at least a 10 point worse score at the one-week follow-
up at home compared to the hospital-based assessment
we found the by far highest frequency for Fatigue
(50.3%), followed by Role Functioning (33.0%), Sleeping
Disturbances (32.3%), Nausea/Vomiting (30.9%), and
Global Quality of Life (30.0%). The smallest proportions
were observed for Diarrhoea (6.8%) and Financial Impact
(10.5%). All other scales showed frequencies between
15% and 30%.
Sensitivity analysis
Further analysis was done to investigate how robust our
results are against changes in the definition of the time
windows for the individual time points.
Narrowing down the time window from 7 and 14 days
plus/minus 3 days as in the main analysis to plus/minus
2 days reduced number of assessments included in the
analysis from 561 to 480. For this time point definition
the estimated means differed from the main analyses
only slightly. For seven of the 45 comparisons (15 scales
- three time points) differences to the main analysis were
between 1.0 and 1.9 points whereas all other deviations
were below 1.0 point. Further restriction of the time
window to plus/minus 1 day allowed 426 assessments to
be analyzed. Deviations from the original means were
between 1.0 and 2.0 points for 11 comparisons and 2.4
and 2.9 points for two comparisons. As these deviations
were well below thresholds for clinical relevance we
consider these results as indicating sufficient robustness
of the main results.
For further exploratory analysis we split the time vari-
able in five smaller categories (0, 4–7, 8–11, 12–15 and
16–17 days after CT administration) to identify the peak
in QOL impairments in an exploratory way to guide
future studies. As five categories come with 10 pairwise







, 2w(70.2-79.4) 78.8 1w(74.1-83.6) F = 13.32; p < 0.001
Ho(61.3-72.9) 68.5 Ho(62.5-74.6) F = 6.22; p = 0.002
, 2w(51.1-63.0) 62.2 1w(55.9-68.4) F = 11.16; p < 0.001
o, 2w(63.1-72.6) 70.8 1w(65.9-75.7) F = 6.66; p = 0.001
o, 2w(82.4-90.3) 89.8 1w(85.6-93.9) F = 6.91; p = 0.001
Ho(57.0-65.0) 62.5 Ho(58.3-66.7) F = 12.1; p < 0.001
(LSD-test).
bold letters.
Table 3 EORTC QLQ-C30 symptom domains and time point of questionnaire completion (54 patients, 561 QOL
assessments)





effect) F/p valuesEstimated mean (95% CI)
Fatigue 34.2 1w, 2w(29.2-39.3) 43.3 Ho, 2w(38.2-48.3) 39.8 Ho, 1w(34.4-45.1) F = 21.40; p < 0.001
Nausea/Vomiting 6.1 1w(3.3-8.9) 12.7 Ho, 2w(9.8-15.5) 8.3 1w(5.2-11.4) F = 19.89; p < 0.001
Pain 18.7(13.5-24.0) 21.7(16.4-27.0) 21.6(16.0-27.1) F = 2.51; p = 0.083
Dyspnoea 22.8 1w(16.1-29.5) 26.3 Ho, 2w(19.6-33.1) 22.9 1w(16.0-29.8) F = 3.92; p = 0.021
Sleeping Disturbances 26.0 1w(20.1-32.0) 34.4 Ho, 2w(28.4-40.5) 29.6 1w(23.3-36.0) F = 12.37; p < 0.001
Appetite Loss 12.8 1w(7.5-18.1) 21.7 Ho, 2w(16.4-27.1) 15.6 1w(9.9-21.3) F = 14.94; p < 0.001
Constipation 13.3 1w, 2w(8.1-18.5) 23.1 Ho(17.8-28.4) 19.4 Ho(13.7-25.2) F = 13.70; p < 0.001
Diarrhoea 7.1(4.1-10.2) 7.3(4.2-10.3) 6.0(2.6-9.3) F = 0.46; p = 0.634
Financial Impact 16.6(10.5-22.7) 18.4(12.3-24.5) 18.9 (12.6-25.1) F = 2.94; p = 0.054
superscript numbers indicate significance (p < 0.05) of post-hoc group comparisons (LSD-test).
score differences to the hospital-based assessment exceeding 5 points are given in bold letters.
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cated that the highest QOL impairments occurred
between day 4 and 7 after CT for Physical Functioning,
Social Functioning, Role Functioning, Fatigue, Appetite
Loss, and Constipation. Between day 8 and 11 the
following scales showed highest impairments: Cognitive
Functioning, Global QOL, Nausea/Vomiting, and Finan-
cial Impact. For Emotional Functioning, Pain, Dyspnoea,
Sleep Disturbances and Diarrhoea score differences
between these two periods (i.e. 4–7 and 8–11 days) were
below 1 point and higher levels were higher than at the
other three periods (i.e. at hospital, or 12–15 and 16–17
days).
Discussion
Our study showed that in CT outpatients patient-
reported symptom burden and functioning impairments
are most severe one week after CT administration. Ac-
cording to the one-week time frame of the QLQ-C30
this assessment covers those days immediately following
CT administration. For 9 out of the 15 QOL domains


















Figure 1 EORTC QLQ-C30 functioning scores at the hospital
and 1 and 2 week(s) later at home. Dashed lines indicate that
differences between hospital- and home-based assessments do not
reach clinical relevance (i.e. a 5 point difference [11]).assessment at the day of CT and one week later
exceeded the threshold for a minimal important clinical
change [11], with strongest increase in burden found for
Fatigue, Constipation, and Appetite Loss. Two weeks
after administration impairment levels mostly recovered
to those assessed at the time of the outpatient hospital
visit. These results indicate that assessments taking place
at the hospital at the time of CT administration under-
estimate true symptom burden experienced by the
patient in the following week, i.e. when s/he is usually at
home.
Due to the heterogeneity of the sample our analysis
did not allow detailed conclusions for specific CT
regimens. However, one would expect that heterogeneity
of diagnosis and treatment results in blurred symptom
trajectories not showing a clear pattern of delayed side
effects one week after treatment that decrease before the
next hospital visit. Given that our data still allowed
clearly identifying such a pattern, this effect may be
rather uniform across patient groups and might be con-



















Figure 2 EORTC QLQ-C30 symptom scores at the hospital and 1
and 2 week(s) later at home. Dashed lines indicate that differences
between hospital- and home-based assessments do not reach clinical
relevance (i.e. a 5 point difference [11]); non-significant scores not shown.
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(mean age 59 years), since completing the PRO
measures on the internet requires a certain degree of
computer-literacy. Albeit, provision of tablet PCs to pa-
tients helped to include also patients not being familiar
with computers, using them only infrequently or not at
all before study participation. Although this affects the
validity of the absolute scores, i.e. the means at the
various time points, the mean differences are probably
more robust. For example, the for a cancer population
rather low mean age of 59 years probably gives a biased
estimate of the Physical Functioning means, whereas the
effect, that Physical Functioning is lowest one week after
CT administration and then recovers, is probably also
valid for older cancer patients.
A strength of our study is that we had the same mode of
administration (electronic) in the hospital and at home, so
we could rule out a mode of administration effect that
would have been introduced by collecting PRO data e.g.
on a tablet PC at the hospital and via phone interview at
home. Statistical power of the main analysis was sufficient
as indicated by statistically significant differences that are
below the threshold for clinical relevance.
We consider our findings to be well in line with
clinicians’ expectations concerning trajectories of acute
side effects and with the literature. The analysis of Pater
et al. [4] on the optimal timing of completion of the
QLQ-C30 when assessing nausea and vomiting in anti-
emetic trials found that accurate assessment of quality of
life should be based on an assessment time point and a
recall period covering the first three days after CT
administration (e.g. a seven day recall period with an
assessment at day 8 after chemotherapy administration).
Inadequate timing led to clinically relevant differences of
clinical trial results. As in our study QOL deteriorated
during the first week following chemotherapy adminis-
tration. Hakamies-Blomqvist et al. [5] showed that in a
trial comparing docetaxel and methotrexate combined
with 5-fluorouracil, timing of assessment had an impact
on patients’ reports of e.g. Global QOL, Physical Func-
tioning, Fatigue, and Nausea. Whereas that study only
compared correctly (i.e. at the day of treatment or up to
four days earlier) against incorrectly timed assessments,
a more recent analysis of three EORTC trials on CTs
done by Ediebah et al. [3] compared early, accurate, and
late PRO assessments. The authors found that QOL
assessments with the QLQ-C30 at the day of CT admin-
istration did not differ from those up to 10 days prior to
chemotherapy administration. However, similar to our
study QOL assessments made up to ten days after CT
administration showed stronger impairments. In all three
trials Nausea/Vomiting was worse when assessed up to
10 days after administration (3–6 points), and in two of
three trials this was also observed for Fatigue (4–8 points),Appetite Loss (5–7 points) and Social Functioning (4–6
points).
Such findings have several implications for conducting
PRO assessments. First, they underline the importance
of following a strict schedule when assessing PRO in a
clinical trial, as deviations may alter results. Second,
these studies demonstrate the importance of incorporat-
ing specific hypotheses on the course of PRO domains
in a trial design. Third, PRO assessments at the day of
treatment administration may in general underestimate
true symptom burden as side effects develop after the
assessment and may disappear before the subsequent
assessment.
Naturally, as patients often attend the hospital only for
treatment administration and spend time between treat-
ments at home, more adequate timing of PRO assess-
ments requires patients to complete questionnaires
outside the hospital. An obvious, while not the only,
method of collecting data while patients are not in the
hospital is the use of web-sites where patients can log on
and complete PRO instruments. The feasibility of this
method for data collection has been demonstrated in
various cancer patient populations [16-18]. Despite an
increase in computer and internet literacy in elderly
populations [19], the implementation of a routine web-
based PRO assessment still remains challenging.
Conclusion
In conclusion, we think that our findings should encour-
age researchers and clinicians to schedule PRO assess-
ments not only in accordance with clinical events or
fixed follow-up time points, but also to rely on consider-
ations on hypothesised symptom trajectories. In chemo-
therapy patients QOL assessments only at the day of CT
administration underestimate the true symptom burden.
Based on our results and the literature we recommend
to assess QOL also one week after CT administration
when patients are at home. This may help to obtain a
more complete picture of the burden and impairments a
patient is confronted with. The comprehensive understand-
ing of patients’ symptom burden is crucial for treatment
optimization and individualisation, as such knowledge may
help to optimize supportive care during chemotherapy.
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